No connection

Search Results

BEAM vs ICUI

BEAM
Beam Therapeutics Inc.
BEARISH
Price
$31.56
Market Cap
$3.2B
Sector
Healthcare
AI Confidence
65%
ICUI
ICU Medical, Inc.
BEARISH
Price
$125.68
Market Cap
$3.14B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
BEAM
--
ICUI
4189.33
Forward P/E
BEAM
-6.85
ICUI
13.66
P/B Ratio
BEAM
3.22
ICUI
1.46
P/S Ratio
BEAM
57.5
ICUI
1.41
EV/EBITDA
BEAM
-4.93
ICUI
13.35

Profitability

Gross Margin
BEAM
0.0%
ICUI
36.84%
Operating Margin
BEAM
-1307.6%
ICUI
4.83%
Profit Margin
BEAM
0.0%
ICUI
0.03%
ROE
BEAM
-47.19%
ICUI
0.04%
ROA
BEAM
-23.48%
ICUI
1.66%

Growth

Revenue Growth
BEAM
-32.0%
ICUI
-14.1%
Earnings Growth
BEAM
--
ICUI
--

Financial Health

Debt/Equity
BEAM
0.16
ICUI
0.63
Current Ratio
BEAM
6.02
ICUI
2.39
Quick Ratio
BEAM
5.89
ICUI
0.99

Dividends

Dividend Yield
BEAM
--
ICUI
--
Payout Ratio
BEAM
0.0%
ICUI
0.0%

AI Verdict

BEAM BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and profitability concerns. Despite a strong analyst recommendation of 'strong_buy' and a target price implying 44% upside, the company exhibits negative gross and operating margins, deteriorating revenue growth, and deeply negative returns on equity and assets. Insider selling activity totaling $3.19M over the past six months contradicts the bullish analyst sentiment, while valuation multiples like a Price/Sales ratio of 57.50 are extremely stretched relative to fundamentals. Although the current ratio is strong at 6.02, suggesting near-term liquidity safety, the lack of Altman Z-Score and persistent unprofitability elevate long-term sustainability risks.

Strengths
Exceptionally strong liquidity position with a current ratio of 6.02 and quick ratio of 5.89, providing runway for R&D and operations
Low debt burden with a Debt/Equity ratio of 0.16, well below sector average of 2.71, reducing financial risk
Analyst consensus is strongly bullish with a 'strong_buy' rating from 15 analysts and a mean target price of $45.47
Risks
Critically low Piotroski F-Score of 1/9 signals severe financial distress and poor fundamental strength
Operating margin of -1307.60% and gross margin of 0.00% indicate no viable path to profitability in the near term
Revenue growth is sharply negative at -32.00% YoY, reversing prior growth trends and signaling weakening commercial momentum
ICUI BEARISH

ICUI presents a stark contradiction between a strong balance sheet and a collapsing income statement. While the Piotroski F-Score of 8/9 indicates exceptional structural financial health, the company is suffering from a severe earnings crisis, evidenced by a P/E ratio of 4189.33 and a -131.5% Q/Q EPS growth. The massive disconnect between the current price ($125.68) and the Graham Number ($7.62) suggests the stock is trading at a significant premium based on future recovery hopes rather than current fundamentals. With revenue declining by 14.1% and insiders selling, the strong health score is currently insufficient to offset the operational deterioration.

Strengths
Strong Piotroski F-Score (8/9) indicating high structural health
Healthy Current Ratio (2.39) showing strong short-term liquidity
Manageable Debt/Equity ratio (0.63)
Risks
Severe earnings collapse with recent Q/Q EPS growth of -131.5%
Negative revenue growth (-14.10% YoY) indicating market share loss or demand drop
Extreme valuation disconnect (Current P/E 4189.33 vs Forward P/E 13.66)

Compare Another Pair

BEAM vs ICUI: Head-to-Head Comparison

This page compares Beam Therapeutics Inc. (BEAM) and ICU Medical, Inc. (ICUI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile